Originally launched in 2022, the collaboration between SOPHiA GENETICS and AstraZeneca Spain established HRD testing in five labs across the country. Within just six weeks, these labs were operational, processing tumor samples efficiently. To date, over 4,000 samples have been analyzed, covering approximately 90 percent of HRD testing in Spain.

Building on this success, AstraZeneca Spain has named SOPHiA GENETICS as its preferred partner for HRD testing deployment across Spain. Together, they offer the option for HRD testing to be available in additional laboratories, facilitating in-house HRD detection. This initiative aims to expedite diagnostics by enhancing the volume and speed of next-generation sequencing (NGS) testing and tumor profiling. Through the deployment of the SOPHiA DDM™ Platform, the collaboration seeks to accelerate diagnostics and support clinicians in precision treatment planning.

Marta Moreno, Director of Corporate Affairs and Market Access at AstraZeneca Spain, emphasized the importance of precision medicine in improving cancer treatment outcomes. She highlighted the agreement with SOPHiA GENETICS as a step towards offering accurate diagnoses for ovarian cancer patients across Spain.

Kevin Puylaert, Managing Director, EMEA at SOPHiA GENETICS, expressed enthusiasm for expanding the testing program across local diagnostic facilities in Spain. He emphasized the program's potential to enhance patient care and contribute to global data on HRD, further advancing treatment options for ovarian cancer patients.

HRD, a significant predictor of tumor response to certain treatments, affects various cancers, including advanced ovarian cancer. With approximately half of newly diagnosed ovarian cancer patients having HRD-positive tumors, access to HRD testing is crucial for guiding treatment decisions and improving outcomes.